Company Watch

Ethypharm licenses cardio product to Ranbaxy

Our News Bureau - Mumbai

Ethypharm India announced out-licensing and supply contract agreements for a fixed dose combination of Fenofibrate micronized 160 milligram and Atorvastatin 10 milligram with Ranbaxy, which will be launched in the Indian market.

This deal comes after a similar deal that Ethypharm had signed with Ranbaxy for out-licensing and supply of Tramadol Flashtab this year. The products will be supplied from Ethypharm's manufacturing facility near Mumbai, as finished and packaged formulations. They will be marketed and distributed by Ranbaxy under their brand name Storfib. According to Ajey Kumar, Chief Executive Officer of Ethypharm India, "This product encapsulates the benefits of both combination offerings and drug delivery technologies. They will help the large Indian populace, who suffer from mixed dyslipidemia, which is a common culprit in the Asian sub-continent, including India." Commenting on the agreement, Sanjeev I Dani, Regional Director India and Middle East of Ranbaxy said, "Ranbaxy in India is the leader in novel drug delivery system products and a pioneer in the lipids management portfolio as well. Storfib very aptly symbolises both these strengths and would further augment our leadership position in the cardiovascular market."